1-(2-{4-[3-(4-Fluoro-phenyl)-indan-1-yl]-piperazin-1-yl}-ethyl)-imidazolidin-2-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 1-(2-{4-[3-(4-Fluoro-phenyl)-indan-1-yl]-piperazin-1-yl}-ethyl)-imidazolidin-2-one
• 英文别名: 1-[2-[4-[3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]piperazin-1-yl]ethyl]imidazolidin-2-one
• 化学式: C₂₄H₂₉FN₄O
• 分子量: 408.5
• InChiKey: GHAMYXPEZSUOCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  38.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(2-{4-[3-(4-Fluoro-phenyl)-indan-1-yl]-piperazin-1-yl}-ethyl)-imidazolidin-2-one 、 L-(-)-二苯甲酰酒石酸 生成 (2R,3R)-2,3-dibenzoyloxybutanedioic acid;1-[2-[4-[(1R,3S)-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]piperazin-1-yl]ethyl]imidazolidin-2-one
  参考文献：
  名称：

  VZHUSTOGESPUSTO, KLAUS R.;ARNT, JZHUSTORN;VOESK, VITA;SNRISTENSEN, A.VIVE+, J. MED. CHEM., 31,(1988) N 12, C. 2247-2256

  摘要：

  DOI：
• 作为产物：
  描述：

  cis 1-[3-(4-fluorophenyl)-indan-1-yl]piperazine 、 1-(2-氯乙基)-2-咪唑啉酮 生成 1-(2-{4-[3-(4-Fluoro-phenyl)-indan-1-yl]-piperazin-1-yl}-ethyl)-imidazolidin-2-one
  参考文献：
  名称：

  VZHUSTOGESPUSTO, KLAUS R.;ARNT, JZHUSTORN;VOESK, VITA;SNRISTENSEN, A.VIVE+, J. MED. CHEM., 31,(1988) N 12, C. 2247-2256

  摘要：

  DOI：

文献信息

• Indane derivatives and methods of preparation and treatment
  申请人：H. LUNDBECK A/S

  公开号：EP0183349A1

  公开（公告）日：1986-06-04

  Indane derivatives with the formula: wherein R1 is H, Halogen, an alkyl group having from one to three carbon atoms inclusive, methoxy, a methylthio-group, or a trifluoromethyl group, n is 2-4, X is O or S, Y is 0, CH2 or N-R2, where R2 is hydrogen or an (1-6 C) alkyl, (1-6 C) alkenyl or cycloalkyl-methyl group having from three to six carbon atoms, Z is -(Ch2)n-, n is 2 or 3 or Z is 1,2-phenylene optionally substituted with halogen or trifluoromethyl or Z = 1,2-C6H4CO- (to form a quinazolidinone or -thione ring system). U = N or C, geometric isomers thereof as well as pharmaceutically acceptable acid addition salts are potent 5-HT2 antagonists useful in the treatment of cardiovascular diseases including hypertension and anxiety. Methods for the preparation of said compounds are also described.

  式中的茚满衍生物： 其中 R1 是 H、卤素、含 1 至 3 个碳原子的烷基、甲氧基、甲硫基或三氟甲基、 n 为 2-4、 X 是 O 或 S、 Y 是 0、CH2 或 N-R2，其中 R2 是氢或 (1-6 C) 烷基、 (1-6C)烯基或环烷基甲基，具有 3 至 6 个碳原子。 至六个碳原子的 (1-6 C) 烷基、(1-6 C) 烯基或环烷基甲基、 Z 是-(Ch2)n-，n 是 2 或 3，或 Z 是被卤素或三氟甲基任选取代的 1,2-亚苯基。 或 Z = 1,2-C6H4CO-（形成喹唑啉酮或硫酮环系）。 U = N 或 C、 其几何异构体以及药学上可接受的酸加成盐是强效的 5-HT2 拮抗剂，可用于治疗心血管疾病，包括高血压和焦虑症。 还描述了制备上述化合物的方法。
• VZHUSTOGESPUSTO, KLAUS R.;ARNT, JZHUSTORN;VOESK, VITA;SNRISTENSEN, A.VIVE+, J. MED. CHEM., 31,(1988) N 12, C. 2247-2256
  作者：VZHUSTOGESPUSTO, KLAUS R.、ARNT, JZHUSTORN、VOESK, VITA、SNRISTENSEN, A.VIVE+

  DOI：——

  日期：——
• TREATING INFLAMMATION AND RELATED CONDITIONS WITH IRINDALONE
  申请人：Ore Pharmaceuticals Inc.

  公开号：EP2323662A1

  公开（公告）日：2011-05-25
• METHODS FOR TREATING INFLAMMATION AND RELATED CONDITIONS
  申请人：Malstrom Scott

  公开号：US20100069400A1

  公开（公告）日：2010-03-18

  A method for treating an inflammatory condition or immune disorder comprises administering to a subject having such a condition or disorder a therapeutically effective amount of at least one compound selected from irindalone, physiologically active enantiomers thereof, and pharmaceutically acceptable salts thereof. The invention further provides a method for elevating levels of anti-inflammatory cytokines such as IL-10 and IL-13 while inhibiting expression of pro-inflammatory cytokines. A pharmaceutical composition, useful for example in topical treatment of psoriasis, comprises a therapeutically effective amount of at least one compound selected from irindalone, physiologically active enantiomers thereof, and pharmaceutically acceptable salts thereof, in a vehicle comprising at least one pharmaceutically acceptable excipient, the vehicle being adapted for topical administration to skin of a subject.
• US4684650A
  申请人：——

  公开号：US4684650A

  公开（公告）日：1987-08-04